References
- McLeod HL, Parodi L, Sargent DJ, et al. UGT1A1*28, toxicity and outcome in advanced colorectal cancer: Results from Trial N9741. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I, Vol. 24, No. 18S (June 20 Supplement), 2006: 3520.
- Hoskins JM and McLeod HL. UGT1A1*28 and irinotecan-induced neutropenia: dose matters. (Submitted for publication.)
- Goldberg RM, Sargent DJ, Morton RF, et al Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A North American Intergroup Trial. J. Clin Oncol. 2006;24(21):3347–53.
- McLeod HL, Watters JW: Irinotecan pharmacogenetics: Is it time to intervene? J Clin Oncol. 2004;22(8):1356–1359.
- Meyerhardt JA, Kwok A, Ratain MJ, et al. Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(8):1439–46.